Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Malignant Disease × Paclitaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 333 Carcinoma, Non-Small-Cell Lung 260 Ovarian Neoplasms 175 Lung Neoplasms 129 Neoplasms 92 Fallopian Tube Neoplasms 76 Carcinoma, Ovarian Epithelial 63 Neoplasm Metastasis 59 Esophageal Neoplasms 58 Stomach Neoplasms 50 Head and Neck Neoplasms 45 Squamous Cell Carcinoma of Head and Neck 44 Triple Negative Breast Neoplasms 40 Endometrial Neoplasms 36 Adenocarcinoma of Lung 32 Urinary Bladder Neoplasms 28 Esophageal Squamous Cell Carcinoma 26 Unspecified Adult Solid Tumor, Protocol Specific 24 Uterine Cervical Neoplasms 22 Melanoma 22 Carcinoma 22 Breast Neoplasms, Male 22 Small Cell Lung Carcinoma 20 Prostatic Neoplasms 20 Adenocarcinoma Of Esophagus 20 Recurrence 19 Parkinson Disease 4, Autosomal Dominant Lewy Body 18 Brenner Tumor 18 Adenocarcinoma, Bronchiolo-Alveolar 18 Peritoneal Neoplasms 15

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡